



ILC 2024
Leuven, Belgium



Session 1.3: Dormancy: clinical challenges and experimental modeling

Philippe Aftimos, Elia Biganzoli, Patrick Derksen, Rita Mukhtar, Lori Petitti,
François Richard, Claire Turner



Topics presented

1. Understanding the biology of tumor dormancy
2. Therapeutic approaches for preventing/reducing the risk of relapse
3. Liquid biopsy and tumor dormancy
4. Patient perspectives

Gaps, Challenges and possible solutions

1. Fundamental research, Models , cues, the clinical problem

1. develop 'ideal models' (ductal models are not adequate?)
2. Compare non dormant v dormant ILC, use autopsy programs and clinical samples
3. Use models and clinical samples to identify dormancy signals

2. Clinical research

1. Why more CTCs in Lobular? Does this correspond to more dormancy and long latency relapses??
2. Standardization of the liquid biopsy assays (CTC, ctDNA). Active disease v dormant cells.

3. Patient perspectives

1. What is the role of exercise in preventing relapse?
2. Are there differences in dormancy between ethnic groups
3. Tumor v patiënt biology, effects on awakening cues
4. Sustaining dormancy would be a good treatment option (patient advocates)